Pharmabiz5d
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome
US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...
Medscape3mon
Mycosis Fungoides
Mycosis fungoides (MF) is the most common type of ... Photopheresis is an option for SE9zary syndrome, a variant of MF. With treatment and regular check-ups remission may be achieved and the ...
Innate: Lacutamab Treatment Program Moves Forward With Potential Expansion
Innate Pharma's Sezary Syndrome treatment shows strong results. Learn why IPHA stock offers potential with phase 2 data and ...
GlobalData on MSN6d
Innate’s lacutamab gains FDA breakthrough therapy designation
Innate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat ...
Hosted on MSN11mon
Pipeline moves: Prospects drop after investigator-led trial of Roche’s Tecentriq terminated
The drug’s PTSR decreased by 14 points to 19% in cutaneous T-cell lymphoma, 17 points to 16% in Sezary syndrome, and 20 points to 21% in mycosis fungoides. PTSR is the probability, given as a ...
Nasdaq6d
Innate Pharma : FDA Grants Breakthrough Therapy Designation To Lacutamab For R/R Sezary Syndrome
Lacutamab previously received a Fast Track designation by the FDA in 2019 for the treatment of adult patients with relapsed or refractory Sezary syndrome who have received at least two prior ...
Oncology Nurse Advisor9d
CD70-Directed CAR-T Therapy Shows Promise in T-Cell Lymphoma
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
Morningstar6d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Mycosis fungoides, and Sézary syndrome, its leukemic variant, are the most common CTCL subtypes. The overall 5-year survival rate, which depends in part on disease subtype, is approximately 10% ...
Stockhouse6d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Mycosis fungoides, and Sézary syndrome, its leukemic variant, are the most common CTCL subtypes. The overall 5-year survival rate, which depends in part on disease subtype, is approximately 10% for ...
Yahoo Finance6d
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab.